CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...8889909192939495969798...39323933»
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Talzenna (talazoparib) / Pfizer
    Journal, BRCA Biomarker, PARP Biomarker:  FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer. (Pubmed Central) -  Jul 22, 2024   
    Additionally, the CDK4/6 inhibitor palbociclib enhanced the sensitivity of breast cancer cells to talazoparib through FANCI inhibition. These findings highlight the potential of targeting FANCI to enhance the efficacy of PARP inhibitors in treating breast cancer.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
    Journal, Oncolytic virus:  Disentangling Anti-Tumor Response of Immunotherapy Combinations: A (Pubmed Central) -  Jul 22, 2024   
    Additionally, this platform allows us to investigate not only the contribution of processes related to the viral kinetics and dynamics on tumor response, but also the influence of its interaction with an ICI. Additionally, the model can be used to explore different scenarios aiming to optimize treatment combinations and support clinical development.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Case: A Case of Pembrolizumab Induced Myocarditis and Complete Heart Block. (Pubmed Central) -  Jul 22, 2024   
    Rare instances of conduction side effects have been described including brady and tachyarrhythmias, heart block and even cardiac arrest. We present a case of Pembrolizumab induced myocarditis and persistent third-degree heart block.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Pembrolizumab-induced Myasthenia Gravis and Myocarditis. (Pubmed Central) -  Jul 22, 2024   
    While neurologic irAE are underrepresented in literature, their consequences could lead to fatal outcomes. In this report, we describe the case of a patient with excellent performance status prior to pembrolizumab therapy who subsequently suffered myasthenic crisis eventually requiring tracheostomy and long-term mechanical ventilation.
  • ||||||||||  Darzalex Faspro (daratumumab/hyaluronidase) / J&J
    Journal, HEOR:  Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries. (Pubmed Central) -  Jul 22, 2024   
    The resulting total savings over the 5-year time horizon of the model for Hamad Medical Corporation, Sultan Qaboos University Hospital/Royal Hospital, Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital were QAR -2?522?686, OMR -143?214, AED -30?010?627, and AED -5?003?471, respectively. The introduction of dara-SC as a front-line treatment for NDMM patients in Qatar (Hamad Medical Corporation), Oman (Sultan Qaboos University Hospital, Royal Hospital-MOH), and the UAE (SSMC and Tawam Hospital) can help save resources and minimize constraints on the healthcare system.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  QT-RIBRATING: A Deep Learning Method to Evaluate QT on Ribociclib (clinicaltrials.gov) -  Jul 22, 2024   
    P=N/A,  N=70, Recruiting, 
    This case underscores the potential efficacy of avacopan in managing ANCA vasculitis post-acute phase, offering hope for improved outcomes in this challenging condition. Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Jul 2024 --> May 2026
  • ||||||||||  Darzalex (daratumumab) / J&J
    Trial completion date, Trial primary completion date:  DEDALO: A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov) -  Jul 22, 2024   
    P2,  N=45, Active, not recruiting, 
    Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Jul 2024 --> May 2026 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Retrospective data, Journal:  Schnitzler's Syndrome-Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort. (Pubmed Central) -  Jul 22, 2024   
    All patients received NSAIDs and antihistamines, as well as biologics, including the anti-B-cell drug rituximab (1), monoclonal ABs to IgE omalizumab (2, 1 without effect and 1 with partial effect), IL-1i canakinumab (n = 10, 58.8%) subcutaneously once every 8 weeks, and anakinra (n = 4, 23.5%) subcutaneously daily...The onset in adulthood, the presence of recurrent urticarial rashes in combination with fever and other manifestations of a systemic inflammatory response are indications for examination for monoclonal secretion. The use of short- or long-acting IL-1i is a highly effective and safe option in the treatment of such patients.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche
    Journal:  A 95-year-old patient suffered high-grade B-cell lymphoma combined hairy cell leukemia. (Pubmed Central) -  Jul 22, 2024   
    To summarize, a 95-year-old man diagnosed with two types of lymphomas, high-grade B-cell lymphoma and hairy cell leukemia, was successfully treated with venetoclax after other treatments failed. This case suggests that targeted therapy can be effective and safe for super-aged patients with multiple malignant lymphatic system diseases.
  • ||||||||||  cusatuzumab (ARGX-110) / OncoVerity
    Phase classification, Trial completion date, Trial primary completion date, Combination therapy:  ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jul 22, 2024   
    P1,  N=61, Active, not recruiting, 
    T cell responses to vaccine were observed but further work will be required to improve efficacy. Phase classification: P1b --> P1 | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
  • ||||||||||  Opdivo (nivolumab) / BMS
    Clinical, Retrospective data, Journal:  Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study. (Pubmed Central) -  Jul 22, 2024   
    This retrospective multicenter study included RCC patients with BMs receiving nivolumab as second-line therapy or beyond...Elevated sodium levels (?140 mEq/L) pre- and post-ICI treatment correlate with better survival outcomes in mRCC patients with BMs. This finding suggests sodium level assessment as a potential prognostic factor in these patients and warrants further investigation, particularly in combination immunotherapy settings.
  • ||||||||||  B007 / Shanghai Pharma
    Enrollment open:  A Clinical Study of B007 in the Treatment of Pemphigus. (clinicaltrials.gov) -  Jul 22, 2024   
    P2/3,  N=132, Recruiting, 
    The CAR T-cell products highlighted in this review are FDA-approved products, which include Kymriah Not yet recruiting --> Recruiting
  • ||||||||||  ICT01 / ImCheck Therap
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Checkpoint inhibition, Metastases:  EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov) -  Jul 22, 2024   
    P1/2,  N=150, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed, Enrollment change, Metastases:  ATLAS: Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (clinicaltrials.gov) -  Jul 22, 2024   
    P2,  N=5, Active, not recruiting, 
    Phase classification: P1/2 --> P2 Recruiting --> Active, not recruiting | N=50 --> 5
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer (clinicaltrials.gov) -  Jul 22, 2024   
    P1/2,  N=5, Terminated, 
    Recruiting --> Active, not recruiting | N=50 --> 5 N=18 --> 5 | Trial completion date: Dec 2023 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Mar 2024; Slow recruitment